Angelini Chemicals

News & publications

  1. CPhI Japan

    International business platform in the pharmaceutical sector. CPhI Japan is Japan's most comprehensive pharma event, which brings together more than 20,000 pharma industry professionals from 55+ countries.

  2. CDMO - CRDMO: tools and different business model for new opportunity in synthesis

    The active pharmaceutical ingredient (API) is the foundation of a final drug product and is a crucial consideration when choosing a Contract Development and Manufacturing Organisation (CDMO) or Contract Research (in House) Development and Manufacturing Organisation (CRDMO).

Who we are

Our services

R&D

  1. API expertise

    Angelini’s strength in API Research & Development is proven by being the partner of choice for large pharma and smaller biotech companies seeking integrated drug development solutions to accelerate R&D pipelines from bench to market.

  2. Kilo-lab

    Angelini R&D team can rapidly develop scalable, robust and cost-effective chemical synthesis that can be readily transferred to our kilo-labs either as a proof of concept study, or for scale-up and delivery of material to support your early clinical supply as well as small volume API and HPAPI.